Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study

References

• World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization; 2021.
   Google Scholar
• World Health Organization. The END TB Strategy. Geneva: World Health Organization; 2015.
   Google Scholar
• Tiberi S, Walzl G, Vjecha MJ, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018;18(7):e183–e198. doi:10.1016/S1473-3099(18)30110-5
   PubMed Web of Science ®Google Scholar
• Fitzpatrick C, Hui Z, Lixia W, et al. Cost-effectiveness of a comprehensive programme for drug-resistant tuberculosis in China. Bull World Health Organ. 2015;93(11):775–784. doi:10.2471/BLT.14.146274
   Web of Science ®Google Scholar
• Bada FO, Okpokoro E, Blok N, et al. Cost of three models of care for drug-resistant tuberculosis patients in Nigeria. BMC Infect Dis. 2019;19(1):41. doi:10.1186/s12879-018-3636-1
   Web of Science ®Google Scholar
• Yu W. Technical guidance group of the fifth national TB epidemiological survey, the office of the fifth national TB epidemiological survey 2010. Chin J Antitubercul. 2012;34(8):485–508.
   Google Scholar
• World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2020.
   Google Scholar
• Lu Z, Jiang W, Zhang J, et al. Drug resistance and epidemiology characteristics of multidrug-resistant tuberculosis patients in 17 provinces of China. PLoS One. 2019;14(11):e0225361. doi:10.1371/journal.pone.0225361
   Web of Science ®Google Scholar
• World Health Organization. Treatment Guidelines for Drug Resistant Tuberculosis, 2016 Update. Geneva: World Health Organization; 2016.
   Google Scholar
• World Health Organization. Definitions and Reporting Framework for Tuberculosis– 2013 Revision. Geneva: World Health Organization; 2014.
   Google Scholar
• World Health Organization. Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. World Health Organization; ‎2018.
   Google Scholar
• Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017;17(1):573. doi:10.1186/s12879-017-2662-8
   PubMed Web of Science ®Google Scholar
• Sharma N, Khanna A, Chandra S, et al. Trends & treatment outcomes of multidrug-resistant tuberculosis in Delhi, India (2009–2014): a retrospective record-based study. Indian J Med Res. 2020;151(6):598–603. doi:10.4103/ijmr.IJMR_1048_18
   PubMed Web of Science ®Google Scholar
• Bastos ML, Cosme LB, Fregona G, et al. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17(1):718. doi:10.1186/s12879-017-2810-1
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-1
   PubMed Web of Science ®Google Scholar
• Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013. Clin Microbiol Infect. 2018;24(4):381–388. doi:10.1016/j.cmi.2017.07.008
   PubMed Web of Science ®Google Scholar
• Li Q, Shi CX, Lu M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Medicine. 2020;99(30):e21296. doi:10.1097/MD.0000000000021296
   Web of Science ®Google Scholar
• Pradipta IS, Van’t Boveneind-Vrubleuskaya N, Akkerman OW, Alffenaar JC, Hak E. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005–2015. Antimicrob Resist Infect Control. 2019;8:115. doi:10.1186/s13756-019-0561-z
   Web of Science ®Google Scholar
• Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6(1):7. doi:10.1186/s40249-016-0214-x
   PubMed Web of Science ®Google Scholar
• Kuaban A, Balkissou AD, Ekongolo MCE, Nsounfon AW, Pefura-Yone EW, Kuaban C. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon. Pan Afr Med J. 2021;38:229. doi:10.11604/pamj.2021.38.229.28317
   PubMed Web of Science ®Google Scholar
• Tupasi TE, Garfin AM, Kurbatova EV, et al. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012–2014. Emerg Infect Dis. 2016;22(3):491–502. doi:10.3201/eid2203.151788
   PubMed Web of Science ®Google Scholar
• Wekunda PW, Aduda DSO, Guyah B. Determinants of tuberculosis treatment interruption among patients in Vihiga County, Kenya. PLoS One. 2021;16(12):e0260669. doi:10.1371/journal.pone.0260669
   Web of Science ®Google Scholar
• Van LH, Phu PT, Vinh DN, et al. Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: a retrospective study. BMC Infect Dis. 2020;20(1):164. doi:10.1186/s12879-020-4887-1
   PubMed Web of Science ®Google Scholar
• Hannah HA, Miramontes R, Gandhi NR. Sociodemographic and clinical risk factors associated with tuberculosis mortality in the United States, 2009–2013. Public Health Rep. 2017;132(3):366–375. doi:10.1177/0033354917698117
   PubMed Web of Science ®Google Scholar
• Bhering M, Duarte R, Kritski A. Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis. 2021;25(4):292–298. doi:10.5588/ijtld.20.0887
   Web of Science ®Google Scholar
• Xia H, Zheng Y, Liu D, et al. Strong increase in moxifloxacin resistance rate among multidrug-resistant mycobacterium tuberculosis isolates in China, 2007 to 2013. Microbiol Spectr. 2021;9(3):e0040921. doi:10.1128/Spectrum.00409-21
   PubMed Web of Science ®Google Scholar
• Li D, Hu Y, Werngren J, et al. Multicenter study of the emergence and genetic characteristics of Pyrazinamide-resistant tuberculosis in China. Antimicrob Agents Chemother. 2016;60(9):5159–5166. doi:10.1128/AAC.02687-15
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17(1):711. doi:10.1186/s12879-017-2761-6
   PubMed Web of Science ®Google Scholar
• Park S, Jo KW, Shim TS. Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility. Int J Tuberc Lung Dis. 2020;24(2):233–239. doi:10.5588/ijtld.19.0314
   PubMed Web of Science ®Google Scholar
• Juma SP, Maro A, Pholwat S, et al. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania. BMC Infect Dis. 2019;19(1):129. doi:10.1186/s12879-019-3757-1
   PubMed Web of Science ®Google Scholar
• Shi J, Su R, Zheng D, et al. Pyrazinamide resistance and mutation patterns among multidrug-resistant Mycobacterium tuberculosis from Henan Province. Infect Drug Resist. 2020;13:2929–2941. doi:10.2147/IDR.S260161
   PubMed Web of Science ®Google Scholar
• El Hamdouni M, Bourkadi JE, Benamor J, Hassar M, Cherrah Y, Ahid S. Treatment outcomes of drug resistant tuberculosis patients in Morocco: multi-centric prospective study. BMC Infect Dis. 2019;19(1):316. doi:10.1186/s12879-019-3931-5
   Web of Science ®Google Scholar